Kefauver-Harris Amendment of 1962

Kefauver-Harris Amendment of 1962

The 1962 Kefauver-Harris Amendment origins lie in Senate Anti-Trust and Monopoly Subcommittee Chairman Estes Kefauver’s (D-TN) hearings into the drug industry. The hearings revealed staggeringly high profits and a shockingly low level of accountability. The Kefauver hearings depicted an industry out of control: where the costs of medicine were far higher than expenses warranted, where many pharmaceutical ads were blatantly misleading or overstated, research was less than rigorously carried out, and cheaper generic drugs were hard to access. The Keafauver-Harris bill leveled controls on the pharmaceutical companies, forcing them to tell doctors about the side-effects of their products, requiring companies to notify the FDA before product testing on humans, requiring that drug companies prove their drugs worked as claimed (while removing those that didn’t from the market), and forcing companies let their patents run out after a certain number of years, thus allowing their products to be sold cheaply as generic drugs. In short, the law expanded the FDA’s authority to regulate drugs for both safety and efficiency.

Commentary

US Capitol building

Darrel Issa’s Government Handover

January 05, 2011

Cry Wolf Quotes

An unfettered exercise of power is certainly beneficial to no one, and governmental departments are no exception to this rule.

-
Edward J. Breck, president of John H. Breck Inc. (a major cosmetics firm), Testimony, House Committee on Interstate and Foreign Commerce hearings.

I feel that additional legislation…is only helpful to large industry and has a tendency to throttle small industry...

-
Edward J. Breck, president of John H. Breck Inc. (a major cosmetics firm), Testimony, House Committee on Interstate and Foreign Commerce hearings.

It is important to public health, therefore, that Government regulations should not hamstring the medical advances produced by the industry. Disease and death can result from unnecessary delay in permitting a lifesaving drug to reach the public…

-
Eugene M. Beesley, Chairman of the Board of Directors of the Pharmaceutical Manufacturers Association (PMA). Testimony, House Committee on Interstate and Foreign Commerce hearings.

If overcautious and restrictive Government regulation had blocked [penicillin] testing and introduction twenty years ago, some lives would have been saved while a multitude of lives would have been lost.

-
Eugene M. Beesley, Chairman of the Board of Directors of the Pharmaceutical Manufacturers Association (PMA). Testimony, House Committee on Interstate and Foreign Commerce hearings.

Backgrounders & Briefs

Good Rules: Ten Stories Of Successful Regulation

Demos looks at ten laws and rules that we take for granted.